Cite
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia.
MLA
Durben, Michael, et al. “Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia.” Molecular Therapy, vol. 23, no. 4, Apr. 2015, pp. 648–55. EBSCOhost, https://doi.org/10.1038/mt.2015.2.
APA
Durben, M., Schmiedel, D., Hofmann, M., Vogt, F., Nübling, T., Pyz, E., Bühring, H.-J., Rammensee, H.-G., Salih, H. R., Große-Hovest, L., & Jung, G. (2015). Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia. Molecular Therapy, 23(4), 648–655. https://doi.org/10.1038/mt.2015.2
Chicago
Durben, Michael, Dominik Schmiedel, Martin Hofmann, Fabian Vogt, Tina Nübling, Elwira Pyz, Hans-Jörg Bühring, et al. 2015. “Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia.” Molecular Therapy 23 (4): 648–55. doi:10.1038/mt.2015.2.